Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amneal Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amneal to Report Third Quarter 2024 Results on November 8, 2024
October 08, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
October 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
September 23, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
September 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
August 20, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Second Quarter 2024 Financial Results
August 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
August 07, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
July 29, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Second Quarter 2024 Results on August 9, 2024
July 11, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
July 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
July 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Releases 2023 Environmental, Social and Governance Report
June 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
June 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conference
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports First Quarter 2024 Financial Results
May 03, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
April 24, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
April 16, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report First Quarter 2024 Results on May 3, 2024
April 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
March 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
March 25, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
March 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
February 27, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conference
February 13, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
January 31, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
January 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
January 04, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Announces Move to Nasdaq
December 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
December 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit